KR960030938A - 나프틸 화합물, 중간체, 조성물 및 방법 - Google Patents

나프틸 화합물, 중간체, 조성물 및 방법 Download PDF

Info

Publication number
KR960030938A
KR960030938A KR1019960004619A KR19960004619A KR960030938A KR 960030938 A KR960030938 A KR 960030938A KR 1019960004619 A KR1019960004619 A KR 1019960004619A KR 19960004619 A KR19960004619 A KR 19960004619A KR 960030938 A KR960030938 A KR 960030938A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
ococ
oco
pyrrolidinyl
Prior art date
Application number
KR1019960004619A
Other languages
English (en)
Inventor
데이비드 팔코비쯔 알렌
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR960030938A publication Critical patent/KR960030938A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용되는 염을 제공한다:
상기 식에서, R1은 -H, -OH, -O(C1-C4알킬), -OCOC6H5, -OCO(C1-C6알킬), 또는 -OSO2(C2-C6알킬)이고; R2는 -H, -OH, -O(C1-C4알킬), -OCOC6H5, -OCO(C1-C5알킬), -CSO2(C2-C6알킬) 또는 할로이고; R3는 1-페피리디닐, 1-피롤리디닐, 메틸-1-피롤리디닐, 디메틸-1-피롤리디노, 4-모르폴리노, 디메틸아미노, 디에틸아미노, 디이소프로필아미노, 또는 1-헥사메틸렌이미노이고, n은 2 또는 3이다.
또한 본 발명은 하기 일반식(III)의 화합물 또는 그의 약학적으로 허용되는 염을 제공한다:
상기 식에서, Rla는 -H 또는 -OR5이고, 이때 R5는 하이드록시 보호기이고, R2a는 -H, 할로, 또는 -OR6이고, 이때 R6은 하이드록시 보호기이고, R4는 -OH 또는 -CHO이다.
더욱더 본 발명은 일반식(Ⅰ)의 화합물의 약학 조성물 및 그 중에서도 특히 폐경기후 증후군의 증상 및 호르몬에 의존하는 암, 특히 유방암을 완화시키는데 일반식(Ⅰ)의 화합물을 사용하는 방법을 제공한다.

Description

나프틸 화합물, 중간체, 조성물 및 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용되는 염:
    상기 식에서, R1은 -H, -OH, -O(C1-C4알킬), -OCOC6H5, -OCO(C1-C6알킬), 또는 -OSO2(C2-C6알킬)이고; R2는 -H, -OH, -O(C1-C4알킬), -OCOC6H5, -OCO(C1-C6알킬), -OSO2(C2-C6알킬) 또는 할로이고; R3는 1-피페리디닐, 1-피롤리디닐, 메틸-1-피롤리디닐, 디메틸-1-피롤리디노, 4-모르폴리노, 디메틸아미노, 디에틸아미노, 디이소프로필아미노, 또는 1-헥사메틸렌이미노이고, n은 2 또는 3이다.
  2. 제1항에 있어서, R1이 -OH이고, R2가 -OH이고, R3가 1-피페리디닐이고, n이 2인 화합물 또는 그의 약학적으로 허용되는 염.
  3. 활성 성분으로 제1 또는 제2항에 청구된 화합물과 임의로, 에스트로겐 또는 프로게스틴을 그에 대해 약학적으로 허용되는 하나 이상의 담체, 부형제, 또는 희석제와 함께 포함하는 약학 제형.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960004619A 1995-02-28 1996-02-26 나프틸 화합물, 중간체, 조성물 및 방법 KR960030938A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/395,950 US5998401A (en) 1995-02-28 1995-02-28 Naphthyl compounds, intermediates, compositions, and methods
US08/395,950 1995-02-28

Publications (1)

Publication Number Publication Date
KR960030938A true KR960030938A (ko) 1996-09-17

Family

ID=23565221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960004619A KR960030938A (ko) 1995-02-28 1996-02-26 나프틸 화합물, 중간체, 조성물 및 방법

Country Status (32)

Country Link
US (5) US5998401A (ko)
EP (1) EP0729951B1 (ko)
JP (1) JPH08268881A (ko)
KR (1) KR960030938A (ko)
CN (2) CN1053886C (ko)
AR (2) AR001036A1 (ko)
AT (1) ATE180776T1 (ko)
AU (1) AU694837B2 (ko)
BR (1) BR9600821A (ko)
CA (1) CA2170337A1 (ko)
CO (1) CO4700421A1 (ko)
CY (1) CY2178B1 (ko)
CZ (1) CZ288213B6 (ko)
DE (1) DE69602638T2 (ko)
DK (1) DK0729951T3 (ko)
ES (1) ES2132841T3 (ko)
FI (1) FI115524B (ko)
GR (1) GR3030407T3 (ko)
IL (1) IL117168A (ko)
IN (1) IN182138B (ko)
MX (1) MX9600743A (ko)
MY (1) MY113232A (ko)
NO (1) NO305833B1 (ko)
NZ (1) NZ286072A (ko)
PE (1) PE28497A1 (ko)
PL (1) PL183578B1 (ko)
RU (1) RU2167849C2 (ko)
SG (1) SG55098A1 (ko)
TR (1) TR199600126A1 (ko)
TW (1) TW349946B (ko)
YU (1) YU11496A (ko)
ZA (1) ZA961291B (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
CA2213814A1 (en) * 1996-08-29 1998-02-28 Henry Uhlman Bryant Naphthalene compounds, intermediates, formulations, and methods
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
EP1142862A3 (en) * 1996-08-29 2002-10-02 Eli Lilly And Company Naphthyl and tetralone derivatives as intermediates
CA2214931A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorene compounds and method of use
CA2214929A1 (en) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphthofluorene compounds, intermediates, compositions and methods
CA2214935A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Benzofluorene compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
PA8444901A1 (es) * 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
JP2001513501A (ja) 1997-08-07 2001-09-04 イーライ・リリー・アンド・カンパニー エストロゲン阻害活性を有する１−［４−（置換アルコキシ）ベンジル］ナフタレン化合物
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
EP1173164A2 (en) * 1999-04-16 2002-01-23 AstraZeneca AB Estrogen receptor-beta ligands
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
KR100370597B1 (ko) * 2000-06-22 2003-02-05 박정일 산형매립초로부터 분리한 신규한 나프탈렌계 화합물 및이를 유효성분으로 하는 약학적 조성물
WO2002044119A2 (en) * 2000-11-28 2002-06-06 Eli Lilly And Company Synthesis of 2-aryl-1-naphthol derivatives via a tandem palladium catalyzed arylation and dehydrogenation
JP2004531559A (ja) * 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
DE60327931D1 (de) 2002-07-22 2009-07-23 Lilly Co Eli Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten
US9315539B2 (en) * 2002-10-01 2016-04-19 Yale University 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
CN100348192C (zh) * 2003-02-25 2007-11-14 伊莱利利公司 晶状的非溶剂化1－(4－(2－哌啶基乙氧基)苯氧基)－2－(4－甲磺酰基苯基)－6－羟基萘盐酸化物
EP1601356A1 (en) 2003-02-25 2005-12-07 Eli Lilly and Company Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
CA2544501A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
CA2544517A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
WO2005073204A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
CN1910167B (zh) * 2004-01-22 2011-08-10 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
US20070066595A1 (en) 2004-01-22 2007-03-22 Dodge Jeffrey A Selective estrogen receptor modulators
AU2005258085A1 (en) * 2004-06-22 2006-01-05 Smithkline Beecham Corporation Chemical compounds
JP5548205B2 (ja) * 2008-09-29 2014-07-16 イーライ リリー アンド カンパニー 選択的エストロゲン受容体調節因子
KR20160088947A (ko) 2010-06-16 2016-07-26 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en) * 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3313853A (en) * 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
GB1138163A (en) * 1965-05-21 1968-12-27 Bristol Myers Co Benzothiophene derivatives having anti-fertility properties
US3394125A (en) * 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US3483293A (en) * 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) * 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
US3862323A (en) 1971-09-20 1975-01-21 Betz Laboratories Dioxide slime control composition and its use
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8705174D0 (en) * 1987-03-05 1987-04-08 Ici Plc Heterocyclic compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use
US5424334A (en) 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
AU694837B2 (en) 1998-07-30
US6355632B1 (en) 2002-03-12
YU11496A (sh) 1999-03-04
FI960889A0 (fi) 1996-02-26
CN1053886C (zh) 2000-06-28
TW349946B (en) 1999-01-11
US5574190A (en) 1996-11-12
ZA961291B (en) 1997-08-19
RU2167849C2 (ru) 2001-05-27
BR9600821A (pt) 1997-12-23
US5567712A (en) 1996-10-22
DE69602638T2 (de) 1999-10-21
MY113232A (en) 2001-12-31
CY2178B1 (en) 2002-08-23
CZ288213B6 (en) 2001-05-16
FI960889A (fi) 1996-08-29
PE28497A1 (es) 1997-08-27
CN1152683C (zh) 2004-06-09
ES2132841T3 (es) 1999-08-16
IL117168A0 (en) 1996-06-18
CO4700421A1 (es) 1998-12-29
NZ286072A (en) 1996-10-28
NO305833B1 (no) 1999-08-02
GR3030407T3 (en) 1999-09-30
DE69602638D1 (de) 1999-07-08
US5998401A (en) 1999-12-07
CA2170337A1 (en) 1996-08-29
MX9600743A (es) 1997-02-28
JPH08268881A (ja) 1996-10-15
PL312829A1 (en) 1996-09-02
PL183578B1 (pl) 2002-06-28
CN1137525A (zh) 1996-12-11
EP0729951A1 (en) 1996-09-04
FI115524B (fi) 2005-05-31
IL117168A (en) 2001-11-25
CN1261534A (zh) 2000-08-02
IN182138B (ko) 1999-01-09
AR001036A1 (es) 1997-08-27
AU4573296A (en) 1996-09-05
NO960772L (no) 1996-08-29
AR002964A1 (es) 1998-05-27
TR199600126A1 (tr) 1996-10-21
ATE180776T1 (de) 1999-06-15
CZ58196A3 (en) 1996-09-11
NO960772D0 (no) 1996-02-26
EP0729951B1 (en) 1999-06-02
US6268361B1 (en) 2001-07-31
DK0729951T3 (da) 1999-06-23
SG55098A1 (en) 1998-12-21

Similar Documents

Publication Publication Date Title
KR960030938A (ko) 나프틸 화합물, 중간체, 조성물 및 방법
KR950031068A (ko) 골다공증의 복합 치료
KR960034164A (ko) 스틸벤 유도체 및 이를 함유하는 약제학적 조성물
KR970705983A (ko) 나프틸 화합물, 그의 중간체, 제조방법, 조성물 및 사용방법(naphthylcompounds, intermediates, processes, compo sitions, and methods)
RU96103632A (ru) Нафтилпроизводные, способ их получения, промежуточные соединения, фармацевтическая композиция
KR950000728A (ko) 포스포네이트 뉴클레오티드 에스테르 유도체
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
KR950008531A (ko) 11-벤즈알독심-17β-메톡시-17α-메톡시메틸-에스트라디엔 유도체, 이의 제조방법 및 이를 함유하는 약제
DE69628246D1 (de) Naphthyl- und Dihydronaphthylverbindungen als Arzneimittel
RU98103465A (ru) Нафтильные и дигидронафтильные промежуточные продукты, соединения, композиции и способы
LV10446B (en) Novel tetrazole derivatives, method for their preparation and pharmaceutical compositions containing them
KR910016660A (ko) 스쿠알렌 에폭시다제 억제제로서의 스쿠알렌의 디-및 테트라-플루오르 유사체
KR970705999A (ko) 타목시펜 및 타목시펜 유사체의 자궁향성 효과를 최소화시키는 방법 (a method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs)
KR960041178A (ko) 신규의 퀴나졸린 화합물 및 활성 성분으로서 이를 함유하는 항종양제
KR900006301A (ko) 1,4-디아자비사이클로[3.2.2]노난의 제조방법
KR890001965A (ko) 스퍼구알린 관련 유도체
FI932641A0 (fi) Nytt estradiolderivat-klorambucil-konjugat, foerfarande foer dess framstaellning och farmaceutiska kompositioner
KR940007001A (ko) 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
KR960031454A (ko) 벤조티오펜 화합물, 중간 생성물, 조성물 및 방법
KR850001207A (ko) 수용성 리팜피신 유도체의 제조방법
KR960703940A (ko) 에스트라디올의 15,15-디알킬 치환 유도체(15,15-Dialkyl-Substituted Derivatives of Estradiol)
KR970704463A (ko) 스트렙토그라민 유도체, 이의 제조 방법 및 이를 함유하는 약학 조성물(streptogramine derivatives, preparation of same and pharmaceutical compositions containing same)
KR970705387A (ko) 자궁내막암의 억제 방법(methods of inhibiting endometrial cancer)
PT832881E (pt) Compostos de benzofluoreno intermediarios composicoes e metodos
EA199900588A1 (ru) Стероиды, замещенные в положении 11, способ их получения, их применение в качестве лекарственного средства и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application